Mesothelioma Immunotherapy Receives Orphan Drug Designation
A novel therapy for mesothelioma has been given orphan drug designation by the U.S. Food and Drug Administration. Avenge Bio, a biotechnology company working on a new treatment platform for immunotherapy, announced it was granted the designation for its drug AVB-001 in June. It is currently enrolling patients in ongoing phase 1 and phase 2 […]
The post Mesothelioma Immunotherapy Receives Orphan Drug Designation appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.